Barclays lowered the firm’s price target on Alvotech (ALVO) to $4 from $5 and keeps an Underweight rating on the shares. The firm expects the shares to “remain in a holding pattern” pending U.S. approvals in Q4. Alvotech’s financial flexibility “bears watching” given its high leverage, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO:
- Alvotech: Regulatory Setbacks Priced In, Biosimilar Strength Supports Buy Rating Despite Lowered Target
- Alvotech price target lowered to $6 from $10 at UBS
- Alvotech price target lowered to $4 from $5 at Barclays
- Alvotech Posts Strong 2025 Growth, Adds Approvals and New CEO as Biosimilar Pipeline Expands
- Is ALVO a Buy, Before Earnings?